Interview with ViGenCell CEO Ki Pyeongseok

Blood cancer therapy "'First under the Advanced Regenerative Medicine Act'" administered
Stem cell-derived NK cells take aim at brain tumors

Under a treatment plan for advanced regenerative medicine launched in September 2026, ViGenCell's immune cell therapy VT-EBV-N will be administered to a patient for the first time. It is the first case of an advanced regenerative medicine treatment approved by the government for therapeutic use. A cell therapy previously used only in clinical trials is now entering actual clinical practice.


In an interview with The Asia Business Daily on October 20, ViGenCell CEO Ki Pyeongseok said, "The fact that cancer does not recur means that one of its defining properties has been neutralized. This treatment is the first step toward confirming that possibility in a patient."

First treatment under the Advanced Regenerative Medicine Act before product approval... Recurrence in just 1 of 21 patients over 4 years

VT-EBV-N is a treatment designed to prevent the recurrence of extranodal NK/T-cell lymphoma, a rare blood cancer. T cells taken from a patient's blood are trained to recognize cancer cells infected with the Epstein-Barr virus (EBV) and then infused back into the patient's body. In April 2026, the Ministry of Health and Welfare approved the treatment plan as the first treatment under the revised Act on Advanced Regenerative Medicine and Advanced Biopharmaceuticals. Yeouido St. Mary's Hospital will administer the treatment over 2 years to up to 15 patients at high risk of recurrence after chemotherapy.


The evidence comes from the results of a Phase 2 clinical trial. After following 46 patients for 4 years, researchers found that only 1 of the 21 patients who received VT-EBV-N had a cancer recurrence, and none had died. In the comparison group of 25 patients, only 56% remained recurrence-free for 4 years. The results were presented in May 2026 at the American Society of Clinical Oncology (ASCO) meeting, marking the first time a Korean cell therapy had been featured in a formal oral presentation. "Although it was formally a Phase 2 trial, it was effectively a Phase 3 trial: we set the dose from the outset and compared it with a control group," Ki said. "We could do that because we were confident we had a good chance of success."


ViGenCell CEO Ki Pyeongseok is being interviewed by The Asia Business Daily at the company's headquarters in Geumcheon-gu, Seoul. Photo by Kim Hyunmin.

ViGenCell CEO Ki Pyeongseok is being interviewed by The Asia Business Daily at the company's headquarters in Geumcheon-gu, Seoul. Photo by Kim Hyunmin.

View original image

"Immune cells have not yet evolved to fight cancer"... Changing the approach to evolve NK cells

[Bio Story] 1. ViGenCell Sees Potential in Immune Cells' Evolutionary Power, Reports Success with the "First Advanced Regenerative Medicine Treatment" View original image

The achievement grew out of Ki's idea that immune cells could be used as treatments by harnessing abilities they had already developed through their own evolution. Ki believes that because human life expectancy has increased sharply in a short period, immune cells have not had time to evolve to fight cancer. By contrast, T cells have developed over a long evolutionary period the ability to eliminate virus-infected cells. Building on this, VT-EBV-N targets EBV inside cancer cells rather than the cancer cells themselves. "If you give them the right signal to kill virus-infected cells, they do it effectively," Ki explained. "That's why the treatment has been able to prevent recurrence."


For solid tumors unrelated to viruses, the company has chosen to evolve immune cells in the laboratory. Its follow-on pipeline candidate VC-302 is a CAR-NK therapy made by inserting cancer-recognition genes into induced pluripotent stem cells (iPSCs) and then differentiating them into natural killer (NK) cells. "NK cells tend to stop functioning when their genes are altered. Our know-how lies in finding NK cells that are particularly effective at killing cancer cells," Ki explained. In mouse experiments on brain tumors conducted with Professor Jihoon Pi of Seoul National University Hospital, the tumors disappeared in all 3 trials.


Production cost is also considered a strength of the therapy. Chimeric antigen receptor (CAR) T-cell therapies require each patient's own cells to be processed individually, pushing production costs alone into the hundreds of millions of won and the price of a single dose above KRW 500 million. By contrast, ViGenCell says it can produce a vial of its iPSC-based NK-cell therapy for hundreds of thousands of won. The company says that even with 10 doses, the cost could be reduced to about one-hundredth of the cost of a single CAR-T treatment. ViGenCell's ultimate goal is to mass-produce cell therapies like antibody drugs and supply them to the market.

[Bio Story] 1. ViGenCell Sees Potential in Immune Cells' Evolutionary Power, Reports Success with the "First Advanced Regenerative Medicine Treatment" View original image

Preparing for product approval... "We'll do what the U.S. couldn't"

ViGenCell is preparing data to demonstrate that it can consistently manufacture VT-EBV-N to the same quality for product approval. Its goal is to advance VC-302 to a stage where it can enter clinical trials in the first half of 2027. "Cell therapy is an area that even the U.S. finds challenging, so it's a game where the side that works harder wins," Ki said. "Rather than being a fast follower, I want to lead the way and create cell therapies with a global impact."



Ki Pyeongseok, CEO of ViGenCell, poses during an interview with The Asia Business Daily at the company's headquarters in Geumcheon-gu, Seoul. Sept. 15, 2026. Photo by Kim Hyunmin

Ki Pyeongseok, CEO of ViGenCell, poses during an interview with The Asia Business Daily at the company's headquarters in Geumcheon-gu, Seoul. Sept. 15, 2026. Photo by Kim Hyunmin

View original image
[Bio Story] 1. ViGenCell Sees Potential in Immune Cells' Evolutionary Power, Reports Success with the "First Advanced Regenerative Medicine Treatment" View original image


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing